About the book

With the rise and development of Cardio-Oncology, the early screening and monitoring of cardiotoxicity caused by anticancer therapy are particularly vital. Common screening methods for cardiotoxicity include biomarkers, electrocardiograms, and imaging examinations. Imaging examinations such as speckle tracking echocardiography, cardiac magnetic resonance imaging (CMR), cardiac computed tomography (CCT), and radionuclide myocardial perfusion imaging can screen out cardiac injury earlier and more sensitively, and evaluate cardiac substructure and overall function more comprehensively. CMR is a multi-parameter imaging method, and multiple imaging sequences provide information on anatomy, cardiac function, tissue characteristics, blood flow, or perfusion data, all to have a more comprehensive understanding of the changes in cardiac structure and function after anticancer therapy. CMR has a high diagnostic value for common manifestations of cardiotoxicity, including myocardial ischemia, valvular disease, cardiac dysfunction, myocardial fibrosis, and pericardiac disease. At the same time, compared with traditional echocardiography, CMR is more reproducible, accurate, and sensitive, and it has more advantages in early screening and long-term monitoring.